Amlodipine/azilsartan/hydrochlorothiazide

Drug Profile

Amlodipine/azilsartan/hydrochlorothiazide

Alternative Names: Amlodipine/hydrochlorothiazide/azilsartan; Azilsartan/amlodipine/hydrochlorothiazide; Azilsartan/hydrochlorothiazide/amlodipine; Hydrochlorothiazide/amlodipine/azilsartan; Hydrochlorothiazide/azilsartan/amlodipine; TAK-536/AML/HCTZ; TAK-536TCH

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Class Antihypertensives; Benzimidazoles; Benzothiadiazines; Dihydropyridines; Oxadiazoles; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Essential hypertension

Most Recent Events

  • 04 Jul 2017 Chemical structure information added
  • 10 May 2017 Discontinued - Preregistration for Essential hypertension in Japan (PO) based on the outcomes of market research (Takeda FY2016 Q4 results, May 2017)
  • 01 Jun 2016 Takeda completes a phase III trial in Essential hypertension in Japan (NCT02277691; JapicCTI-142689)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top